ClinicalTrials.gov term: Lymphoma, Non-Hodgkin
126 trials changed in the last 30 days: 4 stopped, 49 with notable changes, 73 with minor changes only.
Recruitment suspended
And 2 more changes in the last 30 days
Shandong Qilu Cell Therapy Engineering Technology Co., LtdEarly Phase 1 NCT07048353 Registry history of NCT07048353 on ClinicalTrials.gov (opens the registry)
Recruitment suspended
National Cancer Institute (NCI)Phase 1 NCT07055477 Registry history of NCT07055477 on ClinicalTrials.gov (opens the registry)
Trial terminated
Also in this update: Primary completion date changed from estimate of Mar 31, 2027 to Aug 28, 2026; Final enrollment: 21 participants (planned 42)
Washington University School of MedicineEarly Phase 1 NCT06636175 Registry history of NCT06636175 on ClinicalTrials.gov (opens the registry)
Recruitment suspended
City of Hope Medical CenterPhase 1/2 NCT05861050 Registry history of NCT05861050 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Mar 13, 2029 to Sep 27, 2029
And 1 more change in the last 30 days
CSL BehringPhase 3 NCT07648264 Registry history of NCT07648264 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2028
National Cancer Institute (NCI)Phase 2 NCT05886036 Registry history of NCT05886036 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jan 2027 to Nov 2027
Also in this update: Study completion pushed from Apr 2028 to Jun 2030
Loxo Oncology, Inc.Phase 3 NCT04662255 Registry history of NCT04662255 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Nov 23, 2027 to Sep 17, 2028
City of Hope Medical CenterPhase 2 NCT07293403 Registry history of NCT07293403 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 2026 to Jul 2027
Also in this update: Study completion pushed from Oct 2026 to Oct 2027
Curis, Inc.Phase 1/2 NCT03328078 Registry history of NCT03328078 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2024 to Dec 31, 2028
Also in this update: Study completion pushed from Dec 31, 2026 to Dec 31, 2030
Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdPhase 1/2 NCT05768529 Registry history of NCT05768529 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 30, 2026 to Sep 30, 2027
BioInvent International ABPhase 1/2 NCT03571568 Registry history of NCT03571568 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 31, 2026 to Jul 31, 2027
Also in this update: Primary endpoint(s) modified; Enrollment increased: 21 → 27 participants
Estrella Immunopharma, Inc.Phase 1/2 NCT06343311 Registry history of NCT06343311 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 2027 to Sep 2028
Eli Lilly and CompanyPhase 1 NCT07226843 Registry history of NCT07226843 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jan 1, 2027 to Jan 1, 2028
Also in this update: Study completion pushed from Jun 1, 2027 to Jun 1, 2029
Olivia Newton-John Cancer Research InstitutePhase 2 NCT05788081 Registry history of NCT05788081 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jul 31, 2026 to Mar 31, 2027
Also in this update: Recruitment opened; Study completion pushed from Jul 31, 2026 to Jul 31, 2027
Shanghai Zhongshan HospitalPhase 2 NCT07012980 Registry history of NCT07012980 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 1, 2026 to Jun 1, 2028
Also in this update: Study completion pushed from May 1, 2027 to Nov 1, 2028
SciTech Development, Inc.Phase 1 NCT04234048 Registry history of NCT04234048 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 25, 2026 to Jun 30, 2027
Also in this update: Study completion pushed from Feb 25, 2027 to Dec 2027
Cellectar Biosciences, Inc.Phase 1 NCT03478462 Registry history of NCT03478462 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Jun 1, 2026 to Dec 1, 2026
University of RochesterPhase 2 NCT03758989 Registry history of NCT03758989 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 1, 2026 to Aug 1, 2027
Also in this update: Study completion pushed from Aug 1, 2027 to Aug 1, 2028
British Columbia Cancer AgencyPhase 1 NCT06208735 Registry history of NCT06208735 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Mar 23, 2027 to Aug 24, 2029
City of Hope Medical CenterPhase 2 NCT05672251 Registry history of NCT05672251 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Aug 2028 to Apr 23, 2026; Final enrollment: 24 participants (planned 100)
Werewolf Therapeutics, Inc.Phase 1/2 NCT06939283 Registry history of NCT06939283 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 69 → 58 locations
Acrotech Biopharma Inc.Phase 3 NCT06072131 Registry history of NCT06072131 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Pell Bio-Med Technology Co., Ltd.Phase 1/2 NCT05326243 Registry history of NCT05326243 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 539 participants (planned 700)
Janssen Research & Development, LLCPhase 3 NCT01804686 Registry history of NCT01804686 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3 NCT06929624 Registry history of NCT06929624 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Nov 12, 2026 to May 23, 2026
HutchmedPhase 2 NCT06601504 Registry history of NCT06601504 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Apr 1, 2028 to Aug 13, 2028
National Cancer Institute (NCI)Phase 2/3 NCT03984448 Registry history of NCT03984448 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Ono Pharmaceutical Co., Ltd.Phase 1 NCT05079282 Registry history of NCT05079282 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Ono Pharmaceutical Co., Ltd.Phase 1 NCT06547528 Registry history of NCT06547528 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
M.D. Anderson Cancer CenterPhase 2 NCT03398161 Registry history of NCT03398161 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Hoffmann-La RocheNot specified NCT05954910 Registry history of NCT05954910 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Apr 1, 2027 to Aug 1, 2027
National Cancer Institute (NCI)Phase 1 NCT04609046 Registry history of NCT04609046 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 2026 to Nov 2026
Miltenyi Biomedicine GmbHPhase 1 NCT03853616 Registry history of NCT03853616 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Nov 2026 to Mar 2027
Also in this update: Study completion pushed from Nov 2029 to Mar 2030
BeOne MedicinesPhase 1/2 NCT05006716 Registry history of NCT05006716 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 116 → 111 locations
The Lymphoma Academic Research OrganisationPhase 3 NCT06284122 Registry history of NCT06284122 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion pushed from Sep 2, 2026 to Feb 23, 2027
City of Hope Medical CenterPhase 2 NCT04484012 Registry history of NCT04484012 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 31, 2027 to Sep 29, 2026; Final enrollment: 74 participants (planned 100)
Beijing Tongren HospitalPhase 2 NCT07461831 Registry history of NCT07461831 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
University of California, DavisPhase 2 NCT05600686 Registry history of NCT05600686 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion pushed from Dec 10, 2020 to Jan 14, 2021; Study completion date changed from estimate of May 2, 2027 to Feb 24, 2022
Alliance for Clinical Trials in OncologyPhase 2 NCT01511562 Registry history of NCT01511562 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Dec 31, 2026 to Aug 28, 2026
David Bond, MDPhase 1/2 NCT03015896 Registry history of NCT03015896 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 31, 2026 to Dec 31, 2026
Northside Hospital, Inc.Phase 2 NCT05909059 Registry history of NCT05909059 on ClinicalTrials.gov (opens the registry)
Trial completed
Fred Hutchinson Cancer CenterPhase 1 NCT05359211 Registry history of NCT05359211 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 40 participants (planned 50)
Gustave Roussy, Cancer Campus, Grand ParisNot applicable NCT06813573 Registry history of NCT06813573 on ClinicalTrials.gov (opens the registry)
Sponsor refiled this as recruiting (was completed)
British Columbia Cancer AgencyNot specified NCT06224309 Registry history of NCT06224309 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
OWKINNot specified NCT06625203 Registry history of NCT06625203 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 278 → 283 locations
And 1 more change in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT06717347 Registry history of NCT06717347 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 3, 2027 to Jun 10, 2027
Also in this update: Study completion pushed from Mar 3, 2027 to Sep 9, 2028
Mayo ClinicPhase 2 NCT06834373 Registry history of NCT06834373 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 18, 2026 to May 15, 2027
Mayo ClinicPhase 2 NCT07285044 Registry history of NCT07285044 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 280 → 285 locations
National Cancer Institute (NCI)Phase 2 NCT03739814 Registry history of NCT03739814 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 68 → 82 locations
AstraZenecaPhase 3 NCT07215585 Registry history of NCT07215585 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 19 → 42 locations
Kite, A Gilead CompanyPhase 3 NCT07479797 Registry history of NCT07479797 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 26 → 32 locations
Merck Sharp & Dohme LLCPhase 2/3 NCT07634471 Registry history of NCT07634471 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 28 → 40 participants
National Cancer Institute (NCI)Phase 2 NCT05907759 Registry history of NCT05907759 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 87 → 95 locations
SWOG Cancer Research NetworkPhase 2 NCT05633615 Registry history of NCT05633615 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 190 → 194 locations
And 1 more change in the last 30 days
Regeneron PharmaceuticalsPhase 3 NCT06091865 Registry history of NCT06091865 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 41 → 46 locations
Merck Sharp & Dohme LLCPhase 1/2 NCT07519772 Registry history of NCT07519772 on ClinicalTrials.gov (opens the registry)
Trial sites reduced: 155 → 150 locations
BeOne MedicinesPhase 3 NCT06742996 Registry history of NCT06742996 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 34 → 37 locations
Corvus Pharmaceuticals, Inc.Phase 3 NCT06561048 Registry history of NCT06561048 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 228 → 235 locations
AstraZenecaPhase 3 NCT06549595 Registry history of NCT06549595 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 14 locations
Autolus LimitedPhase 1 NCT06173518 Registry history of NCT06173518 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 0 → 14 locations
SWOG Cancer Research NetworkPhase 2 NCT07638722 Registry history of NCT07638722 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 6 → 14 locations
National Cancer Institute (NCI)Phase 1 NCT07332507 Registry history of NCT07332507 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 6 → 9 locations
TORL Biotherapeutics, LLCPhase 1/2 NCT07439653 Registry history of NCT07439653 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 17 → 20 locations
BeOne MedicinesPhase 1/2 NCT06697184 Registry history of NCT06697184 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 28 → 34 locations
Kite, A Gilead CompanyPhase 1/2 NCT04989803 Registry history of NCT04989803 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 10 → 13 locations
Tempus AINot specified NCT07154823 Registry history of NCT07154823 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 118 → 173 participants
University of Southern CaliforniaNot specified NCT07259304 Registry history of NCT07259304 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 104 → 113 locations
And 1 more change in the last 30 days
National Cancer Institute (NCI)Phase 2 NCT06649812 Registry history of NCT06649812 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 15 → 19 locations
Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaPhase 2 NCT07126236 Registry history of NCT07126236 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 4 locations
City of Hope Medical CenterPhase 2 NCT06052826 Registry history of NCT06052826 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Mar 2027 to Apr 27, 2026
BeOne MedicinesPhase 3 NCT04002297 Registry history of NCT04002297 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Jan 30, 2027 to Aug 11, 2026
Bristol-Myers SquibbPhase 1/2 NCT06035497 Registry history of NCT06035497 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 467 → 486 locations
Wake Forest University Health SciencesNot specified NCT06418204 Registry history of NCT06418204 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jul 2025 to Jul 2027
Olivia Newton-John Cancer Research InstitutePhase 2 NCT04962126 Registry history of NCT04962126 on ClinicalTrials.gov (opens the registry)
Interventions modified
PfizerPhase 1 NCT03460977 Registry history of NCT03460977 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Apr 2027 to Nov 2031
Also in this update: Primary completion moved earlier from Apr 2027 to Jan 2027
AbbViePhase 1 NCT06667687 Registry history of NCT06667687 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Oct 30, 2028 to Dec 29, 2028
Janssen Research & Development, LLCPhase 1 NCT06788509 Registry history of NCT06788509 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Oct 2028 to Aug 2028
Also in this update: Primary completion moved earlier from Oct 2027 to Aug 2027
University of Michigan Rogel Cancer CenterPhase 1 NCT07532525 Registry history of NCT07532525 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Aug 31, 2028 to Apr 3, 2028
Also in this update: Primary completion date changed from estimate of Jan 31, 2027 to Sep 26, 2026
Washington University School of MedicinePhase 1 NCT05412290 Registry history of NCT05412290 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jun 2026 to Jun 2027
Memorial Sloan Kettering Cancer CenterPhase 3 NCT04459416 Registry history of NCT04459416 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jul 21, 2026 to Jul 13, 2027
City of Hope Medical CenterPhase 2 NCT04783415 Registry history of NCT04783415 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jul 15, 2026 to Jul 15, 2027
Emory UniversityPhase 2 NCT03872180 Registry history of NCT03872180 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 30, 2026 to Jul 30, 2027
Alliance Foundation Trials, LLC.Phase 2 NCT03478514 Registry history of NCT03478514 on ClinicalTrials.gov (opens the registry)
Interventions modified
Mayo ClinicPhase 2 NCT03418038 Registry history of NCT03418038 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Aug 2026 to May 27, 2026
Reid Merryman, MDPhase 2 NCT05783596 Registry history of NCT05783596 on ClinicalTrials.gov (opens the registry)
Interventions modified
Also in this update: Trial arms changed: 13 → 12
American Society of Clinical OncologyPhase 2 NCT02693535 Registry history of NCT02693535 on ClinicalTrials.gov (opens the registry)
Study completion pushed from May 23, 2026 to May 23, 2027
Baylor College of MedicineNot applicable NCT05236764 Registry history of NCT05236764 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jul 29, 2026 to Jun 28, 2027
City of Hope Medical CenterPhase 1 NCT03560752 Registry history of NCT03560752 on ClinicalTrials.gov (opens the registry)
Interventions modified
Also in this update: Trial arms changed: 3 → 4
Washington University School of MedicinePhase 1 NCT05044039 Registry history of NCT05044039 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Aug 15, 2026 to Apr 15, 2027
Also in this update: Primary completion date changed from estimate of Aug 15, 2026 to Apr 22, 2020
Beth ChristianPhase 1 NCT02992522 Registry history of NCT02992522 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Dec 1, 2039 to Dec 1, 2040
Also in this update: Primary completion date changed from estimate of Sep 1, 2025 to Dec 11, 2025
Benjamin TomlinsonPhase 1 NCT04732845 Registry history of NCT04732845 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Genfleet Therapeutics (Shanghai) Inc.Phase 1/2 NCT05934513 Registry history of NCT05934513 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
FamiCordTxPhase 1 NCT06593145 Registry history of NCT06593145 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-15 | NCT07875413 Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory… | AbelZeta Inc. new | Phase 2 |
| 2026-10-08 | NCT07864701 Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers | Chengdu Anticancer Bioscience, Ltd. new | Phase 1/2 |
| 2026-10-07 | NCT07862010 Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute… | Hematology department of the 920th hospital new | Early Phase 1 |
| 2026-09-25 | NCT07842198 Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy | Zealand University Hospital new | Phase 2 |
| 2026-09-16 | NCT07823829 A Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma | UCARsgen Biotech Limited new | Phase 1/2 |
| 2026-09-10 | NCT07812493 Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS… | Pengpeng Xu new | Phase 2 |
| 2026-09-10 | NCT07814170 A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In… | University of West Attica new | |
| 2026-08-06 | NCT07750886 Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin… | Natera, Inc. new |
| Early Phase 1 | 48 | |
| Phase 1 | 352 | |
| Phase 1/2 | 236 | |
| Phase 2 | 595 | |
| Phase 2/3 | 24 | |
| Phase 3 | 121 | |
| Phase 4 | 18 |
Ruijin Hospital (72) · National Cancer Institute (NCI) (70) · City of Hope Medical Center (48) · M.D. Anderson Cancer Center (46) · Memorial Sloan Kettering Cancer Center (40) · Sun Yat-sen University (37) · Institute of Hematology & Blood Diseases Hospital, China (30) · Fondazione Italiana Linfomi - ETS (27) · The First Affiliated Hospital with Nanjing Medical University (21) · Baylor College of Medicine (19)